25 results
The current trial aims to asses the safety of this combination in a phase I trial with olaparib dose escalation during two cycles of 177Lu-DOTATATE in salvage setting in patients with advanced GEP NET, progressive after initial PRRT.
This study is evaluating the preliminary efficacy of UV1-olaparib-durvalumab combination against both olaparib as monotherapy and olaparib-durvalumab combination in maintenance after platinum combination therapy for BRCAwt patients with relapsed…
Primary Objectives• To describe the anti-tumor activity and toxicity of commercially available, targeted anti-cancer drugs used for treatment of patients with an advanced solid tumor, multiple myeloma or non-Hodgkin lymphoma that harbours a genomic…
The primary objective of the study is to describe the pharmacokinetics of Nivolumab (how quickly it is absorbed by the body) when injected under the skin (subcutaneously) with or without rHuPH20. rHuPH20 is an enzyme that can increase the absorption…
Protocol v1.0 31-Mar-2014, paragraph 2.1-2.4, pages 37-39:The primary objective of this study is: - To determine the efficacy of Olaparib maintenance monotherapy compared to placebo by progression free survival (PFS).The secundary objectives of this…